Reported Reactions

Devices › Reagents, 2019-novel coronavirus nucleic acid

Device brand name · Reagents 2019-novel coronavirus nucleic acid

Alinity M Resp-4-Plex Amplification Reagent Kit: medical device reports filed with FDA

630 reports name it, 2021–2023. Manufacturer given most often on reports: Abbott Molecular. Product code QJR.

630
device reports naming the brand
0% of all MAUDE reports · about 118 a year
0
reports, 12 months to August 2026
0 in the 12 months before
100%
classified as malfunction
98.4% across the product code
0%
classified as death, as reported
0 reports · not verified by FDA

630 medical device reports received by FDA name the brand "Alinity M Resp-4-Plex Amplification Reagent Kit" (reagents 2019-novel coronavirus nucleic acid); the manufacturer given most often on reports is Abbott Molecular; received from March 2021 to December 2023. Brand names are as the reporter or manufacturer wrote them, so one product can appear under several spellings.

0 reports arrived in the 12 months to August 2026, and none in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are malfunction (100%); across all reagents, 2019-novel coronavirus nucleic acid reports (product code QJR) death is recorded in 0% and malfunction in 98.4%. Event type is the reporter's classification of the report, not a verified outcome.

The device problems coded most often are false positive result (98.9%), false negative result (1.1%) and failure to calibrate (0.5%). FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Reports by month, five years

065129Sep 2021: 3Oct 2021: 5Nov 2021: 15Dec 2021: 162022Jan 2022: 11Feb 2022: 21Mar 2022: 16Apr 2022: 15May 2022: 7Jun 2022: 12Jul 2022: 5Aug 2022: 7Sep 2022: 101Oct 2022: 22Nov 2022: 114Dec 2022: 1292023Jan 2023: 24Feb 2023: 17Mar 2023: 16Apr 2023: 2May 2023: 1Jun 2023: 0Jul 2023: 2Aug 2023: 0Sep 2023: 1Oct 2023: 12Nov 2023: 6Dec 2023: 82024Jan 2024: 0Feb 2024: 0Mar 2024: 0Apr 2024: 0May 2024: 0Jun 2024: 0Jul 2024: 0Aug 2024: 0Sep 2024: 0Oct 2024: 0Nov 2024: 0Dec 2024: 02025Jan 2025: 0Feb 2025: 0Mar 2025: 0Apr 2025: 0May 2025: 0Jun 2025: 0Jul 2025: 0Aug 2025: 0Sep 2025: 0Oct 2025: 0Nov 2025: 0Dec 2025: 02026Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0

Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.

By year received

02304602021: 8120212022: 46020222023: 892023

Event type and report source

Event type, as classified on the report

Death0%0
Injury0%0
Malfunction100%630
Other0%0
Not given0%0

Who filed the report

Manufacturer report100%630
Voluntary report0%0
User facility report0%0
Distributor report0%0
Not given0%0

Grey bar: all 20,139 reports carrying product code QJR. Event type is the filer's classification and is not verified by FDA.

Device problems coded

Device problem (FDA code)ReportsShareShare across product code
False positive result62398.9%66.6%
False negative result71.1%13.9%
Failure to calibrate30.5%0%

FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.

In context

MeasureAlinity M Resp-4-Plex Amplification Reagent KitProduct code QJRAll MAUDE reports
Reports63020,13926,136,888
Share of that pool—3.1%0%
Classified as death, per 1,000 reports009
Classified as injury0%1.5%36.2%
Classified as malfunction100%98.4%62.3%
Filed by the manufacturer100%98.5%94.9%

Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Other brands with product code QJR

BrandReportsLatest 12 monthsClassified as death
Id Now Covid-19 Assay3,41800%
Cobas Sars-Cov-2 & Influenza A/B Test For Use On The Cobas Liat System2,02600%
Cue Covid-19 Test For Home And Over The Counter Otc Use1,82300%
Id Now Covid-191,13400.4%
Cobas Sars-Cov-2 Test1,08600%
Check-It93000%
Aptima Sars-Cov-2 Assay72600%
ID NOW COVID-19 2.0 Test KIT 24T JAPAN704370%
Alinity M Sars-Cov-2 Amplification Reagent Kit53500%
Id Now Covid 19 Assay52300%
Id Now Covid-19 2 0 Test Kit 24t Ous48900%
Lyra Direct Sars-Cov-2 Assay41500%
Alinity M Resp-4-Plex Amp Kit409690%
Accula Sars Cov-2 Test39100%
Bd Sars-Cov-2 Reagents For Bd Max System35900%

Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."

Questions about Alinity M Resp-4-Plex Amplification Reagent Kit reports

How many FDA reports name Alinity M Resp-4-Plex Amplification Reagent Kit?

630 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 0 in the latest 12 months.

What kinds of events are reported?

malfunction (100%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.

What device problems are coded?

false positive result (98.9%), false negative result (1.1%) and failure to calibrate (0.5%). These are FDA's device problem codes as entered on the report.

Who files these reports?

manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.

Do these reports show that Alinity M Resp-4-Plex Amplification Reagent Kit was at fault?

No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."

How do I report a problem with a medical device?

Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.